Periotrap

PerioTrap Pharmaceuticals is a biotechnology company specializing in the development of innovative therapies for periodontitis, a severe gum disease affecting a significant portion of the global population. The company targets the microbiome, the community of microorganisms living in the mouth, to treat periodontitis more effectively and with fewer side effects compared to traditional methods. Traditional treatments often involve painful procedures and the use of broad-spectrum antibiotics, which can disrupt the natural balance of beneficial bacteria and lead to recurrent infections. PerioTrap's approach aims to shift the microbiome in a way that preserves beneficial bacteria while targeting harmful ones, thereby maintaining biofilm homeostasis and reducing the likelihood of recurrent infections. The company operates in the healthcare and pharmaceutical markets, primarily serving patients suffering from periodontitis and related conditions. PerioTrap's business model involves the development and commercialization of its proprietary drug formulations and delivery systems. Revenue is generated through the sale of these products, as well as through public grants and funding for research and development. The company has received significant public funding to support its non-clinical safety and efficacy studies, further validating its innovative approach.

Keywords: periodontitis, microbiome, biotechnology, drug development, targeted therapy, biofilm homeostasis, gum disease, pharmaceutical, healthcare, innovative treatments.